Moreover, Petros et al reported that detection of TP53 mutations was associated with poor TKI-response in patients with ALK-positive NSCLC.39 These factors may explain the poor outcome after treatment with ceritinib in our patient with parotid adenocarcinoma. This evidence concerns the gene ALK and non-small cell lung carcinoma.